Prognostic value of interferon-γ release assays, a population-based study from a TB low-incidence country

Thorax

Volumn 71, Issue 7, 2016, Pages 652-658

  Hermansen, Thomas Stig ^a,b   Lillebaek, Troels ^b   Kristensen, Kristina Langholz ^a   Andersen, Peter H ^b   Ravn, Pernille ^a  

^a HILLERØD HOSPITAL   (Denmark)

^b STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON;

ADULT; AGE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOKINE RESPONSE; DANISH CITIZEN; DENMARK; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INCIDENCE; INFECTION RISK; INTERFERON GAMMA RELEASE ASSAY; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS TEST KIT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; TUBERCULOSIS; MIDDLE AGED; PREVALENCE; RISK FACTOR;

ADULT; DENMARK; FEMALE; HUMANS; INCIDENCE; INTERFERON-GAMMA RELEASE TESTS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TUBERCULOSIS;

EID: 84973176546     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2015-208228     Document Type: Article

References (36)

1. WHO MC. Global Tuberculosis Report 2014. Vol. 19, 2014.
2. Pai M, Denkinger CM, Kik SV, et al. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev 2014;27:3-20.
3. van Ingen J, de Zwaan R, Dekhuijzen R, et al. Region of difference 1 in nontuberculous Mycobacterium species adds a phylogenetic and taxonomical character. J Bacteriol 2009;191:5865-7.
4. Harboe M, Oettinger T, Wiker HG, et al. Evidence for occurrence of the ESAT-6 protein in Mycobacterium tuberculosis and virulent Mycobacterium bovis and for its absence in Mycobacterium bovis BCG. Infect Immun 1996;64:16-22.
5. Zellweger JP, Sotgiu G, Block M, et al. Risk assessment of tuberculosis in contacts by IFN-? Release Assays. A Tuberculosis Network European Trials Group Study. Am J Respir Crit Care Med 2015;191:1176-84.
6. Sester M, van Leth F, Bruchfeld J, et al. Risk assessment of tuberculosis in immunocompromised patients. A TBNET study. Am J Respir Crit Care Med 2014;190:1168-76.
7. Rangaka MX, Wilkinson KA, Glynn JR, et al. Predictive value of interferon-gamma release assays for incident active tuberculosis: a systematic review and meta-Analysis. Lancet Infect Dis 2012;12:45-55.
8. Sloot R, Schim van der Loeff MF, Kouw PM, et al. Risk of tuberculosis after recent exposure. A 10-year follow-up study of contacts in Amsterdam. Am J Respir Crit Care Med 2014;190:1044-52.
9. Getahun H, Matteelli A, Chaisson RE, et al. Latent Mycobacterium tuberculosis infection. N Engl J Med 2015;372:2127-35.
10. Aichelburg MC, Rieger A, Breitenecker F, et al. Detection and prediction of active tuberculosis disease by a whole-blood interferon-gamma release assay in HIV-1-infected individuals. Clin Infect Dis 2009;48:954-62.
11. Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010;36:1185-206.
12. Bumbacea D, Arend SM, Eyuboglu F, et al. The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement. Eur Respir J 2012;40:990-1013.
13. Lange C, Rieder HL. Intention to test is intention to treat. Am J Respir Crit Care Med 2011;183:3-4.
14. Diel R, Goletti D, Ferrara G, et al. Interferon-gamma release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-Analysis. Eur Respir J 2011;37:88-99.
15. WHO Report. Management of latent tuberculosis infection Guidelines on the management of latent tuberculosis infection. 2015.
16. Hermansen T, Lillebaek T, Hansen AB, et al. QuantiFERON-TB Gold In-Tube test performance in Denmark. Tuberculosis (Edinb) 2014;94:616-21.
17. Browatzki A, Meyer CN. Interferon-gamma release assay on suspicion of active tuberculosis? Ugeskr Laeger 2009;171:2631-5.
18. Haldar P, Thuraisingam H, Patel H, et al. Single-step QuantiFERON screening of adult contacts: a prospective cohort study of tuberculosis risk. Thorax 2013;68:240-6.
19. Kik SV, Franken WP, Mensen M, et al. Predictive value for progression to tuberculosis by IGRA and TST in immigrant contacts. Eur Respir J 2010;35:1346-53.
20. Fong KS, Tomford JW, Teixeira L, et al. Challenges of interferon-gamma release assay conversions in serial testing of health-care workers in a TB control program. Chest 2012;142:55-62.
21. Diel R, Loddenkemper R, Niemann S, et al. Negative and positive predictive value of a whole-blood interferon-gamma release assay for developing active tuberculosis: an update. Am J Respir Crit Care Med 2011;183:88-95.
22. Torres Costa J, Silva R, Ringshausen FC, et al. Screening for tuberculosis and prediction of disease in Portuguese healthcare workers. J Occup Med Toxicol 2011;6:19.
23. Soborg C, Ruhwald M, Andersen PH, et al. 6-year follow-up of 522 HIV-positive individuals screened for Mycobacterium tuberculosis infection in Denmark. Eur Respir J 2014;44(2):540-3.
24. Andersen P. EPINYT, Tuberkulose 2013. 2015. http://www.ssi.dk/Aktuelt/Nyhedsbreve/EPI-NYT/2015/Uge%203%20-%202015.aspx
25. Comstock GW. Epidemiology of tuberculosis. Am Rev Respir Dis 1982;125(Pt 2):8-15.
26. Machingaidze S, Verver S, Mulenga H, et al. Predictive value of recent QuantiFERON conversion for tuberculosis disease in adolescents. Am J Respir Crit Care Med 2012;186:1051-6.
27. Pollock JM, Andersen P. Predominant recognition of the ESAT-6 protein in the first phase of interferon with Mycobacterium bovis in cattle. Infect Immun 1997;65:2587-92.
28. Andersen P, Askgaard D, Ljungqvist L, et al. T-cell proliferative response to antigens secreted by Mycobacterium tuberculosis. Infect Immun 1991;59:1558-63.
29. Doherty TM, Demissie A, Olobo J, et al. Immune responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients. J Clin Microbiol 2002;40:704-6.
30. Pai M, Joshi R, Dogra S, et al. Serial testing of health care workers for tuberculosis using interferon-gamma assay. Am J Respir Crit Care Med 2006;174:349-55.
31. Bakir M, Millington KA, Soysal A, et al. Prognostic value of a T-cell-based, interferon-gamma biomarker in children with tuberculosis contact. Ann Intern Med 2008;149:777-87.
32. Weyer K. Discovery, innovation, and new frontiers in tuberculosis diagnostics: reflections and expectations. J Infect Dis 2015;211(Suppl 2):S78-80.
33. National Collaborating Centre for Chronic Conditions (UK), Centre for Clinical Practice at NICE (UK) 2011.
34. Geis S, Bettge-Weller G, Goetsch U, et al. How can we achieve better prevention of progression to tuberculosis among contacts? Eur Respir J 2013;42:1743-6.
35. Sarivalasis A, Bodenmann P, Langenskiold E, et al. High rate of completion of preventive therapy for latent tuberculosis infection among asylum seekers in a Swiss Canton. Swiss Med Wkly 2013;143:w13860.
36. Seersholm N, Løkke A, Hilberg O, et al. Retningslinjer for undersøgelse for latent og aktiv tuberkulose forud for behandling med TNF-A-hæmmere og andre biologiske lægemidler hos dermatologiske, reumatologiske, gastroenterologiske og lungemedicinske patienter. http://www.lungemedicin.dk/TB%20og%20biologiske%20laegemidler.pdf ed. 2010.